30.07

2.27% -0.70

Kymera Therapeutics Inc (KYMR)

Overview News Price History Option Chain Financials Discussions Forecast

Kymera Therapeutics Inc stock is traded at $30.07, with a volume of 535.92K. It is down -2.27% in the last 24 hours and up +25.55% over the past month. Kymera Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to reinventing the treatment of human disease through the development of, differentiated medicines that address health problems and that meaningfully improve patients' lives. It is committed to novel technologies to address targets that have known disease-causing biology, but which have not been drugged, or have been inadequately drugged, often based on limitations of existing technologies. Its approach is intended to discover and develop a new generation of medicines in a disease-agnostic manner. Its product pipelines are STAT6, TYK2, and IRAK4.

Previous Close:

$30.77

Open:

$33.64

24h Volume:

535.92K

Relative Volume:

0.75

Market Cap:

$2.30B

Revenue:

$87.56M

Net Income/Loss:

$-167.47M

P/E Ratio:

-12.85

EPS:

-2.34

Net Cash Flow:

$-148.20M

1W Performance:

-14.77%

1M Performance:

+25.55%

6M Performance:

-40.98%

1Y Performance:

-22.12%

1-Day Range:

$29.99

$33.64

1-Week Range:

$28.28

$35.32

52-Week Range:

$19.45

$53.27

Kymera Therapeutics Inc Stock (KYMR) Company Profile

Name

Kymera Therapeutics Inc

Sector

Healthcare (1153)

Industry

Biotechnology (676)

Phone

857-285-5314

Address

500 NORTH BEACON STREET, 4TH FLOOR, WATERTOWN

Employee

188

Twitter

Next Earnings Date

2025-02-21

Latest SEC Filings

KYMR's Discussions on Twitter

Compare KYMR with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
KYMR Kymera Therapeutics Inc	30.07	2.30B	87.56M	-167.47M	-148.20M	-2.34
VRTX Vertex Pharmaceuticals Inc	424.99	128.84B	11.10B	-988.90M	-1.26B	-3.92
REGN Regeneron Pharmaceuticals Inc	527.78	65.38B	14.09B	4.50B	2.96B	39.28
ARGX Argen X Se Adr	549.65	39.67B	2.19B	833.04M	-1.28B	12.71
ALNY Alnylam Pharmaceuticals Inc	251.15	33.82B	2.35B	-269.70M	-75.39M	-2.09
ONC Beigene Ltd Adr	231.99	27.60B	3.81B	-644.79M	-669.77M	-6.24

Kymera Therapeutics Inc Stock (KYMR) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Mar-13-25	Initiated	Citigroup	Buy
Dec-10-24	Initiated	BTIG Research	Buy
Dec-06-24	Initiated	BMO Capital Markets	Market Perform
Dec-02-24	Upgrade	Wells Fargo	Equal Weight → Overweight
Nov-18-24	Initiated	Stephens	Overweight
Sep-09-24	Resumed	Leerink Partners	Outperform
Aug-26-24	Upgrade	Wolfe Research	Peer Perform → Outperform
Apr-22-24	Initiated	Oppenheimer	Outperform
Feb-15-24	Initiated	Wolfe Research	Peer Perform
Jan-04-24	Upgrade	JP Morgan	Neutral → Overweight
Jan-03-24	Downgrade	BofA Securities	Buy → Neutral
Dec-19-23	Downgrade	Wells Fargo	Overweight → Equal Weight
Jun-30-23	Initiated	Truist	Buy
May-05-23	Upgrade	Raymond James	Mkt Perform → Outperform
Dec-06-22	Downgrade	Credit Suisse	Outperform → Neutral
Nov-08-22	Initiated	Raymond James	Mkt Perform
Aug-15-22	Initiated	Jefferies	Buy
Aug-03-22	Initiated	Goldman	Buy
Jul-20-22	Initiated	SVB Leerink	Mkt Perform
Apr-28-22	Initiated	Credit Suisse	Outperform
Mar-10-22	Initiated	JP Morgan	Neutral
Feb-10-22	Initiated	Wells Fargo	Overweight
Sep-30-21	Initiated	B. Riley Securities	Neutral
Sep-30-21	Initiated	Stifel	Buy
Sep-10-21	Downgrade	BofA Securities	Buy → Neutral
May-21-21	Initiated	UBS	Buy
Apr-14-21	Initiated	Berenberg	Buy
Dec-04-20	Initiated	H.C. Wainwright	Buy
Sep-15-20	Initiated	BofA Securities	Neutral
Sep-15-20	Initiated	Cowen	Outperform
Sep-15-20	Initiated	Guggenheim	Buy
Sep-15-20	Initiated	Morgan Stanley	Equal-Weight

View All

Kymera Therapeutics Inc Stock (KYMR) Latest News

08:34 AM

Kymera Therapeutics, Inc. (NASDAQ:KYMR) Q1 2025 Earnings Call Transcript - Insider Monkey

08:34 AM

07:00 AM